

Michigan Pharmacy and Therapeutics Committee
Meeting of December 2, 2008
Kellogg Center, Michigan State University
DRAFT DRAFT DRAFT Minutes DRAFT DRAFT DRAFT

Introductions

Committee members present: P. Thill, PharmD, E. Inman, PharmD, J. Dillon, MD, K. Nedd, MD, G. Perri, MD, N. Dorfman, RPh, R. Bradley, DO, J. Fiechtner, MD. Committee members absent: P. Dake, MD, R. Rogers, MD, J. Arend, PharmD. State staff present: D. Eggleston, MD, N. Mattarella, MD, S. Moran, RN, C. Green-Edwards, RN, T. Welch, Pharmacy Analyst. First Health staff present: A. Paul, RPh.

Approval of Minutes of September 9, 2008 Meeting

Minutes were approved as currently published in draft form

New Drug Reviews

Following presentation and discussion, the Committee recommended to the Department:

Cimzia; Add to the Michigan Pharmaceutical Product List (MPPL), and to the Preferred Drug List (PDL) class, “Biologic immunomodulators” without prior authorization (PA)

Relistor: add to the MPPL without PA

Durezol Ophthalmic: Add to the MPPL without PA

Entereg Informational only; this is a hospital service

Trelstar Informational only; this is a physician service

Line Extensions

Following presentation and discussion, the Committee recommended to the Department:

Actonel 150mg: Add to the MPPL and to the PDL with prior authorization

Aldex AN: Do not add this to the MPPL

Liquadd: Do not add this to the MPPL or the PDL

Requip XL: Add to the MPPL and to the PDL class “Non Ergot Dopamine Receptor Agonists” without PA

Evamist: Add to the MPPL with PA

Millipred; Add to the MPPL with PA

Taclonex scalp susp: Add to the MPPL with PA

Papfyll foam: Add to the MPPL with PA

Doryx: Add to the MPPL with age edits to exclude use in young children

Xolegel: Add to the MPPL with PA

Review of Preferred Drug List Classes

Following presentation and review of the workgroup recommendations, the Committee recommended to the Department

Analgesics

Narcotics-Long Acting

Move methadone to this class

Set up edits to require prior authorization if there has been no previous use of other narcotics within the six months before the request for methadone

Edit against use of concurrent other narcotics with methadone

No changes to the current classification of the other drugs

Narcotics-Short and Intermediate Acting

No further changes to the current classification of these drugs beyond reclassifying methadone

Maintain the current editing on Actiq, regarding diagnoses for use and quantity

Maintain edits on Oxycontin use

Non-Steroidal Anti-Inflammatory-COX II

Remove prior authorization from Celebrex but place a quantity limit of 30 tablets maximum per prescription.

Central Nervous System Drugs

Alzheimer's Dementia

No change to the current classification of drug products

Anti-Anxiety General

No change to the current classification of drug products

Drugs for ADHD

Maintain clinical edit on this class

Remove prior authorization from Vyvanse

Put a maximum quantity of 31 per prescription

No changes to the classification of the other drug products

Sedative-Hypnotic Non Barbiturates

Remove prior authorization from Rozerem

Set an edit to require prior authorization if beneficiary has had paid claims for benzodiazepines within the past six months before the prescription for rozerem

No other changes to current classification of drug products, or use of prior authorization for more than three months' use of any drug(s) in the class

Reflect on the PDL that Sonata is now available as a generic

Public Comment

The following persons made comments to the Committee

K. Riddle, AstraZeneca, Crestor

P. Attawalla, MD., Schering Plough, Vytorin, Zetia

K. Krivacic, PhD., Cimzia

Dr. J. Cwengros, Pfizer, Lipitor

E. Zimmerman, MD, Univ Mich, biologic therapies for Crohn's,UC

Setting Dates for 2009 Meetings

Following discussion, the Committee agreed to the following dates for its meetings in 2009: March 3, June 2, September 1, December 1